Tempus AI, founded in 2015 by Groupon co-founder Eric Lefkofsky in Chicago, applies machine learning to genomic and clinical data to help oncologists and other physicians match patients to more precise treatments, building one of the largest connected libraries of clinical and molecular data in the process.
The company went public on Nasdaq under the ticker TEM and reported first-quarter 2026 revenue of $348.1 million, up 36.1% year over year, with diagnostics revenue growing 34.7% on 28% oncology volume growth and its data-and-applications segment growing 40.5%. Tempus raised its full-year 2026 revenue guidance to $1.59 to $1.60 billion, up from roughly $1.27 billion in 2025, while holding $643.8 million in cash as of March 2026.
As a diagnostics and data platform sold to health systems, physicians, and pharmaceutical partners, pricing runs through insurance billing and enterprise data-licensing agreements rather than a published subscription rate. For an oncologist or health system that wants genomic and clinical data matched to precision treatment options, backed by a large, publicly reported, and growing data platform, Tempus AI's scale addresses that directly.
